Cancer Diagnosis, Risk Assessment and Prediction of Therapeutic Response by Means of DNA Methylation Markers | Zendy

Heidi Fiegl | Zendy; Karim Elmasry | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cancer Diagnosis, Risk Assessment and Prediction of Therapeutic Response by Means of DNA Methylation Markers

Author(s) -

Heidi Fiegl,

Karim Elmasry

Publication year - 2007

Publication title -

disease markers

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.912

H-Index - 66

eISSN - 1875-8630

pISSN - 0278-0240

DOI - 10.1155/2007/293138

Subject(s) - dna methylation , cancer , methylation , risk assessment , oncology , dna , medicine , biology , computational biology , bioinformatics , cancer research , genetics , gene , computer science , gene expression , computer security

Epigenetic alterations are heritable changes in gene expression without an accompanying change in primary DNA sequence. Two major mechanisms that cause epigenetic changes are post-translational histone modifications and DNA methylation at cytosine bases within a CpG dinucleotide. Epigenetic defects have turned out to be one of the most common molecular alterations in human neoplasia. Promoter hypermethylation is associated with loss of expression of tumour suppressor genes in cancer. The analysis of aberrant DNA methylation is gaining strength in the fields of cancer risk assessment, diagnosis, and therapy monitoring in different cancer types. These issues are discussed in this review.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research